

Abstract Retyped for Clarity

**Presentation by professor Athena Papas, DMD, Ph.D.
Tufts University/New England Medical Center Hospital, Boston, USA
at the
11th MASCC International Symposium
SUPPORTIVE CARE IN CANCER
Nice, France - February 1999**

An Oral Preventive Protocol for Bone Marrow Transplant Patients.
Athena Papas, DMD, PhD. – Erling Johansen, DMD, PhD. – Kenneth Miller, M.D.

The oral complications Bone Marrow Transplant (BMT) treatment are at minimal extremely painful and at their most severe life threatening. This is a retrospective study on 59 (19 allo, 40 auto) BMT patients to assess the effectiveness of a calcium phosphate rinse in reducing the days of mucositis and neutropenia (below WBC 500).

Twenty patients (Group 1-11 auto, 9 allo) were given a pre BMT oral assessment and all restorations and necessary extractions were completed before treatment. Peridex and nystatin were used during the course of the BMT.

Thirty nine patients (Group 2-30 auto, 9 allo) received the same pre-BMT oral assessment and treatment, but used supersaturated calcium/phosphate rinses Caphosol™ and nystatin during the course of the BMT. Daily medical assessment was done by the BMT Team.

Results: Group 1 had a mean of 15.95 +/- 7.37 of neutropenia and 13.05 +/- 4.89 days of mucositis and Group 2 had a mean of 10.92 +/- 4.66 days of neutropenia and 9.46 +/- 4.36 days of mucositis. Group 2 had significantly lower number of days of mucositis (P = 0.006) and neutropenia (P = 0.002). There were not enough patients to analyze allogenic transplants independently but when autogenous transplants were analyzed for days of neutropenia (Group 1, 13.58 and Group 2, 10.03) the results were still significantly different (P = 0.007). Calcium phosphate rinses have been used in the past years in the management of BMT patients with no deaths due to oral infection. The patients on Caphosol™ go home a day sooner than the control group.

We are currently conducting a double-blind placebo control trial on 120 BMT patients.

Conclusion: The results of this retrospective study demonstrate that a regimen using Caphosol™ can protect the oral mucosa, treat mucositis, and reduce the days of neutropenia. There have been no deaths from oral infection in the fourteen years that Caphosol™ has been used.